Table 3.
Baseline characteristics of the patients with negative/positive D-dimer results
| Males (n = 272) | p value | Females (n = 203) | p value | p value for positive D-dimer in males vs females | |||
|---|---|---|---|---|---|---|---|
| Negative D-dimer |
Positive D-dimer |
Negative D-dimer |
Positive D-dimer |
||||
| n (%) | 146 (53.7) | 126 (46.3) | 141 (69.5) | 62 (30.5) | 0.001 | ||
| Age (years), median (IQR) | 53 (45–61) | 55 (48–62) | 0.120 | 40 (32–48) | 48 (39–55) | 0.001 | < 0.0001 |
| Type of VTE, n (%) | |||||||
| DVT | 82 (56.2) | 65 (51.6) | 0.449 | 70 (49.6) | 25 (40.3) | 0.222 | 0.146 |
| DVT + PE | 35 (24.0) | 34 (27.0) | 0.571 | 24 (17.1) | 14 (22.6) | 0.357 | 0.517 |
| Isolated PE | 29 (19.8) | 27 (21.4) | 0.745 | 47 (33.3) | 23 (37.1) | 0.601 | 0.022 |
| Type of risk factors, n (%) | |||||||
| Idiopathic | 128 (87.7) | 112 (88.9) | 0.760 | 40 (28.2) | 23 (37.1) | 0.218 | < 0.0001 |
| WRFs | 18 (12.3) | 14 (11.1) | 0.760 | 101 (71.6) | 39 (62.9) | 0.218 | < 0.0001 |
| (Total HCT n = 120; n; %) | (89; 74.2a) | (31; 25.8a) | 0.081 | ||||
| Total duration of follow-up for all patients (years) | 234 | 201 | 241 | 107 | |||
| Patients censored during follow-up, n (%) | 11 (7.5) | 12 (9.5) | 0.554 | 3 (2.1) | 4 (6.4) | 0.121 | 0.474 |
| Lost to follow-up, n (%) | 1 (0.7) | 0 (0) | 0.348 | 0 (0) | 1 (1.6) | 0.133 | 0.156 |
| Presence of RVT (> 4 mm), n (%) | 18 (12.3) | 19 (15.1) | 0.502 | 3 (2.1) | 3 (4.8) | 0.294 | 0.039 |
| Associated antiplatelet treatment, n (%) | 10 (6.8) | 6 (4.8) | 0.485 | 2 (1.4) | 0 (0) | 0.350 | 0.080 |
aThese percentages are calculated versus the 120 women whose VTE event occurred during HCT
DVT proximal vein thrombosis, HCT hormonal contraceptive therapy, IQR interquartile range, PE pulmonary embolism, RVT esidual vein thrombosis, VTE venous thromboembolism, WRFs weak risk factors